Literature DB >> 2033030

The role of pimozide in clinical psychiatry: a review.

L A Opler1, S S Feinberg.   

Abstract

Pimozide, a diphenylbutylpiperidine neuroleptic which is FDA-approved as a backup treatment for Gilles de la Tourette's syndrome, has been used abroad for many years as a treatment of schizophrenia and has been recently reported to be particularly effective in treating monosymptomatic hypochondriacal psychosis and delusional jealousy. Pimozide may also have a role in the treatment of negative schizophrenic symptoms, pain syndromes, and obsessive compulsive disorder. After reviewing the relevant clinical literature supporting these indications, the authors review preclinical studies that provide points of departure regarding biochemical mechanisms underlying this unique therapeutic profile.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033030

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.

Authors:  E Suzuki; S Kanba; H Koshikawa; M Nibuya; G Yagi; M Asai
Journal:  J Psychiatry Neurosci       Date:  1996-05       Impact factor: 6.186

2.  USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.

Authors:  Jin-Ku Lee; Nakho Chang; Yeup Yoon; Heekyoung Yang; Heejin Cho; Eunhee Kim; Yongjae Shin; Wonyoung Kang; Young Taek Oh; Gyeong In Mun; Kyeung Min Joo; Do-Hyun Nam; Jeongwu Lee
Journal:  Neuro Oncol       Date:  2015-06-01       Impact factor: 12.300

3.  Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells.

Authors:  Junjun Chen; Thomas S Dexheimer; Yongxing Ai; Qin Liang; Mark A Villamil; James Inglese; David J Maloney; Ajit Jadhav; Anton Simeonov; Zhihao Zhuang
Journal:  Chem Biol       Date:  2011-11-23

Review 4.  Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.

Authors:  R E Kast
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 5.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

6.  The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane.

Authors:  Michal Stark; Tomás F D Silva; Guy Levin; Miguel Machuqueiro; Yehuda G Assaraf
Journal:  Cells       Date:  2020-04-27       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.